![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 47, 45243-45248, November 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, August 5, 2002, and in revised form, September 4, 2002
Mammalian aminoacyl tRNA synthetases form a
macromolecular protein complex with three non-enzymatic cofactors.
Among these factors, p43 is also secreted to work as a cytokine on
endothelial as well as immune cells. Here we investigated the activity
of p43 in angiogenesis and determined the related mediators. It
promoted the migration of endothelial cells at low dose but induced
their apoptosis at high dose. p43 at low concentration activated
extracellular signal-regulating kinase, which resulted in the induction
and activation of matrix metalloproteinase 9. In contrast, p43 at high
concentration activated Jun N-terminal kinase, which mediated apoptosis
of endothelial cells. These results suggest that p43 is a novel
cytokine playing a dose-dependent biphasic role in angiogenesis.
Aminoacyl-tRNA synthetases
(ARSs)1 are essential enzymes
catalyzing the first step of protein synthesis. Several mammalian tRNA
synthetases form a macromolecular protein complex with three auxiliary
factors, p43, p38, and p18 (1-3). However, the structure and function
of this complex have not been fully understood. Although the component
enzymes make specific protein-protein interactions via their
non-catalytic peptide appendices (4-6) as well as catalytic core
domain (7), the assembly and stability of the whole complex are mainly
contributed to by one of the three cofactors, p38 (8), which is in
contact with many components of the complex (9, 10). Because components
dissociated from the multi-ARS complex were subjected to degradation
process, at least one function of the complex formation appears to be
the maintenance of the cellular stability of the complex-forming
enzymes and cofactors (8).
The structure and activity of another complex-associating factor, p43,
have been most extensively studied. It was proposed to be located in
the center of the complex (11) and binds arginyl-tRNA synthetase (12)
as well as tRNA (13) to facilitate the catalysis of the enzyme.
Surprisingly, p43 itself is also secreted to work on immune cells and
triggers pro-inflammatory response (14, 15). In addition, it showed a
potential to interact with the Cell Culture and Materials--
Bovine aorta endothelial cells
(BAECs) were isolated from descending thoracic aortas and grown in
Dulbecco's modified Eagle's medium containing 20% fetal bovine
serum. The primary cells used in this study were between passages 5 and
10. Ac-YVAD-pNA, Ac-DEVD-pNA, and z-DEVD-fmk were
purchased from Calbiochem, and PD98059, SB203580, and SB202190 were
purchased from BIOMOL. The antibodies specific to three
mitogen-activated protein kinases, ERK1/2, p38 MAPK, and JNK, were
obtained from New England BioLabs. JNK dominant negative mutant
(JNK-DN) and Jun-binding domain (JBD) of Jun-interacting protein were
kind gifts from Dr. E. J. Choi (Korea University, Korea). A
Transwell chamber for the endothelial cell migration assay and VEGF
were purchased from Corning and R&D systems, respectively.
Purification of p43 and Its Domains--
p43 (312 aa) and its N
(146 aa)- and C (166 aa)-terminal domains were expressed as His tag
fusion protein in Escherichia coli BL21(DE3) and purified by
nickel affinity and Mono S ion-exchange chromatography (14). To remove
lipopolysaccharide (LPS), the protein solution was dialyzed in
pyrogen-free buffer (10 mM potassium phosphate buffer, pH
6.0, 100 mM NaCl). After dialysis, the p43 solution was
loaded to polymyxin resin (Bio-Rad) pre-equilibrated with the same
buffer, incubated for 20 min, and eluted. To further remove residual
LPS, the protein solution was dialyzed against PBS containing 20%
glycerol and filtered with Posidyne membrane (Pall Gelman laboratory).
The concentration of the LPS in p43 was below 20 pg/ml as determined by
using the Limulus Amebocyte lysate QCL-1000 kit (BioWhittaker).
Angiogenesis Assays--
The activity of p43 in angiogenesis was
determined using various in vitro and in vivo
assays. For chorioallantoic membrane (CAM) assay, fertilized chick eggs
were incubated in the humidified egg breeder at 37 °C. On the third
day of incubation, about 2 ml of egg albumin was removed by an 18-gauge
hypodermic needle to detach the developing CAM from the shell. After
the incubation for an additional 6 days, Thermanox coverslips (Nunc)
loaded with 0, 0.1, or 1 µg of p43 were placed on the CAM surface,
and the remodeling of vascularization was observed after 3 days. The
total length of blood vessels within the area of the coverslips was determined by Image-Pro Plus (Media Cybernetics). For tube formation assay, BAECs (5 × 105 cells) were cultivated on
Matrigel in the presence of 0, 1, or 100 nM p43 at 37 °C
for 18 h. The changes of cell morphology were then captured by
phase-contrast microscopy. For the in vitro cell migration
assay, the cultivated BAECs were wounded with a razor blade and
incubated in the media containing 0, 1, or 100 nM p43. The
cells were allowed to migrate for 16 h, then fixed with absolute methanol and stained with Giemsa. The BAEC migration assays were performed by using a Transwell chamber (24-well chamber) with polycarbonate membranes (8.0-µm pore size, Costar) as described with
slight modifications (22). The wells were coated with 0.5 mg/ml gelatin
(Sigma) in phosphate-buffered saline and allowed to air-dry. BAECs were
suspended in serum-free DMEM and added to the upper chamber at
2-5 × 104 cells per well. A chemotactic stimulus,
VEGF (0.7 nM), or one of the indicated concentrations of
p43 was placed in the lower chamber, and the cells were allowed to
migrate for 7 h at 37 °C in a 5% CO2 incubator.
After incubation, non-migrant cells were removed from the
upper face of the membrane with a cotton swab. The migrant cells (those
attached to lower face) were fixed in 100% methanol and visualized by
the hematoxylin (Sigma) staining. The migrant cells were counted in
high power fields.
Apoptosis Assays--
The in situ apoptosis detection
was performed by using the ApoptagTM fluorescein kit
(Oncor) according to the manufacturer's protocol. Apoptotic nuclei
were visualized by using a confocal laser scanning microscope (Bio-Rad
MRC 1024). To determine the degradation of chromosomal DNA into the
nucleosome-sized fragments, a 500-µl aliquot of the lysis buffer (100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2 M NaCl, 0.2% SDS, and 0.2 mg/ml proteinase K) was added to the cell pellet (2 × 105 cells) and incubated at
37 °C overnight. DNA was obtained by consecutive 1.5 M
NaCl and ethanol precipitation, treated with RNase (200 µg/ml),
separated in a 1.8% agarose gel, and visualized under UV light. For
the caspase assay, BAECs (2 × 106 cells) were treated
with or without p43 (100 nM) for 16 h and then lysed
with 300 µl of the chilled cell lysis buffer (20 mM HEPES, pH 7.5, 1 mM dithiothreitol, 0.1 mM
EDTA, 0.5% Nonidet P-40, and 0.1 mM phenylmethylsulfonyl
fluoride). The cell lysates were centrifuged at 15,000 × g for 5 min at 4 °C, and the supernatant fractions were
used to measure the activities of caspase-1 and -3. The protein
extracts (40 µg) of the cell lysates were incubated for 2 h at
30 °C in the assay buffer (20 mM HEPES, pH
7.5, 2 mM dithiothreitol, and 10% glycerol) containing 100 µM caspase-3 substrate,
Ac-DEVD-p-nitroanilide, or the caspase-1 substrate, Ac-YVAD-p-nitroanilide. The amount of
p-nitroaniline released by the caspase activation was
quantitated by the optical density at 405 nm.
Determination of MAPK Activation and in Vitro JNK Kinase
Assay--
BAECs treated with different concentrations of p43 were
washed twice with cold phosphate-buffered saline, lysed with the lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 12 mM Zymographic Assay--
BAECs were seeded onto six-well plates in
DMEM containing 20% fetal bovine serum, and cultured to 70-80%
confluency. The cells were then washed two times with DMEM with 2%
fetal bovine serum and cultured for additional 2 h, and then p43
was added at the indicated concentrations. After 24 h, the media
were collected and mixed with 5× FOD buffer (4% SDS, 20% glycerol,
0.01% bromphenol blue, and 125 mM Tris-HCl, pH 6.8). The
samples were subjected to 7.5% SDS-PAGE with the gel containing 1 mg/ml gelatin (Sigma). After electrophoresis, the gel was washed two
times with 2.5% Triton X-100, briefly with distilled water, and
incubated with the reaction buffer (50 mM Tris-HCl, pH 7.5, 10 mM CaCl2, 1 µM ZnCl2, 150 mM NaCl, 1% Triton X-100, and
0.002% sodium azide) overnight at 37 °C. The gel was stained with
0.2% Coomassie Brilliant Blue R-250 and destained with 35% methanol.
RT-PCR--
Reverse transcription reaction was performed using
Moloney murine leukemia virus reverse transcriptase (Invitrogen)
following the protocol provided by the manufacturer. The primer
sequences for MMP9 cDNA were 5'-GGCAGCTGGCAGAGGAATACCTGT-3'
(forward) and 5'-GGTGGCGCACCAGCGGTAGCCGTC-3' (reverse). The primer
sequences for glyceraldehyde-3-phosphate dehydrogenase cDNA were
5'-TCATTGACCTCAACTACATG-3' (forward) and 5'-CCAAAGTTGTCATGGATGAC-3'
(reverse). The reaction mixture was first denatured at 95 °C for 5 min, and the PCR condition was 94 °C/1 min, 55 °C/1 min, and
72 °C/1min for 25 cycles, followed by 72 °C for 5 min.
DNA Transfection for Apoptosis--
For gene transfection, BAECs
were grown overnight in six-well plates and washed in Hanks' buffered
salt solution prior to transfection using the method of adenovirus
conjugated to polylysine as described previously (24). Empty vector
(pcDNA3.1) or the vector expressing JNK-DN or JBD (2 µg) were
transfected into BAECs along with 2 µg of the vector expressing
enhanced green fluorescent protein, and expressed for 24 h.
The transfected cells were treated with p43 (20 nM) for
24 h, and then cell death was determined by counting the apoptotic
cells using fluorescence microscopy. The percentage of apoptotic
cells was determined by dividing the number of green cells with
apoptotic morphology with the total number of green cells. Empty vector
was used as the control and gave about 15% or less apoptotic cells.
Dose-sensitive Induction of the Endothelial Cell Migration by
p43--
The activity of p43 in angiogenesis was determined by several
different experiments. In the chorioallantoic membrane assay, the
coverslips loaded with the different amounts of p43 were placed on the
surface of the membrane. In eight out of ten tested eggs, blood vessels
were attracted to the area to which the low dose of p43 (0.1 µg) was
spotted, whereas this effect was not observed at the high dose (1 µg)
(Fig. 1A). The total length of
the blood vessel within the area of the coverslip was ~2.2-fold
increased with 0.1 µg of p43 but about 0.3-fold decreased with 1 µg
of p43 compared with the control. The effect of p43 on tube formation was tested on Matrigel. BAECs were cultivated on Matrigel containing different amounts of p43. The stimulation of tube formation was observed at 1 nM but not at 100 nM p43 (Fig.
1B). Third, the activity of p43 was also tested by wound
migration assay. In this assay, the cultivated BAECs were
scraped with a razor blade and then allowed to migrate in the presence
of different concentrations of p43. The cell migration was enhanced at
1 nM but not at 100 nM p43 (Fig.
1C). Finally, the chemotactic activity of p43 on BAECs was
tested using the Transwell migration system. Different amounts of
p43 were added to the lower chamber, and the cells migrating from the
upper to lower chamber were counted. The migrated cells were stained
with hematoxylin, and the cell counting was performed in high power
fields. The cell migration was increased to about 4-fold at 1 nM p43, but the effect of p43 was decreased at the
concentrations higher than 1 nM (Fig. 1D). Thus,
all of these experimental results suggest that p43 may induce the
endothelial cell migration but the effect is dose-sensitive.
p43 Induces Apoptosis of the Endothelial Cells at High
Concentration--
As shown above, the stimulatory effect of p43 on
the endothelial cell migration was abolished as its concentration was
increased. We have already shown that the endothelial cell
proliferation was blocked at high concentrations of p43 (16). Here we
investigated whether p43 can induce the death of the endothelial cells
at high concentration using BAECs. The effect of p43 on the death of
BAECs was monitored by the cell morphology and other typical markers for apoptosis. The number of apoptotic cells was dramatically increased
from 10 nM p43 (Fig.
2A). The endothelial cell
death was further confirmed at 100 nM p43 by terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling staining,
DNA laddering, and the activation of caspase-3 (Fig. 2, B,
C, and D, respectively). All of the results
indicate that p43 may induce apoptosis of the endothelial cells at
high concentration.
MAPKs Are Differentially Activated by p43--
We have previously
shown that p43 activates three major mitogen-activated protein kinases
(MAPKs) in monocytes (14, 15). Thus, we tested whether these kinases
are also affected by p43 in the endothelial cells. The activity changes
of these proteins were monitored after BAECs were treated with
different concentrations of p43. Although all of the three kinases were
activated by p43, they responded to different concentrations of p43
(Fig. 3). Although ERK was activated from
0.5 nM p43, the activation of JNK was apparent from 10 nM. The activity of p38 MAPK was increased only at 100 nM p43. Based on this result, we expected that ERK and JNK
could be involved in the p43-induced migration and apoptosis of the endothelial cells, respectively.
ERK Is Responsible for the p43-dependent Endothelial
Cell Migration and the Activation of MMP9--
Because the endothelial
cell migration and the activation of ERK occurred at similar
concentration of p43 (about 1 nM), we investigated whether
ERK mediates the induction of the endothelial cell migration by p43.
The activities of ERK and p38 MAPK were suppressed by the treatment of
their specific inhibitors, PD98059 and SB203580, respectively. BAECs
were incubated with each of these inhibitors in the upper chamber of
the Transwell membrane system, and the cell migration was induced with
1 nM p43 in the lower chamber. The cell migration was
specifically inhibited by the treatment of PD98059, suggesting that ERK
is responsible for the p43-induced cell migration (Fig.
4A).
Matrix metalloproteinases (MMPs) secreted by endothelial cells are
considered to play a key role in the processes of the matrix remodeling
and endothelial cell migration during angiogenesis (25, 26).
Particularly the gelatinases, MMP2 and MMP9, capable of degrading
native collagen type IV that is the major constituent of basement
membranes, are involved in the vascular cell migration and invasion
(27, 28). Because we used the gelatin-coated membrane for the Transwell
cell migration assay (Fig. 1D), we tested whether these two
proteinases are involved in the p43-induced cell migration. The
activities of these two enzymes were determined by their ability to
digest gelatin in the gel matrix as described under "Experimental
Procedures." The activity of MMP9 was dramatically enhanced at 1 nM p43 and decreased at the higher concentrations, whereas
MMP2 gradually decreased as the concentration of p43 was increased
(Fig. 4B).
To see whether the p43-induced MMP9 is responsible for the cell
migration, BAECs were treated with different amounts of anti-MMP9 antibody (26), and the cell migration was induced by 1 nM
p43. The cell migration was blocked by the treatment of anti-MMP
antibody in a dose-dependent manner while mock antibody did
not give a significant effect (Fig. 4C), indicating that
MMP9 is directly involved in the p43-induced cell migration. To
determine the functional linkage of MMP9 and ERK in the p43-induced
cell migration, the activity of ERK and the expression and activation
of MMP9 were determined in BAECs treated with 1 nM p43. As
expected, the activation of ERK by p43 was blocked with PD98059 and but
not with SB203580 (Fig. 4D), consistent with the effect of
PD98059 on the p43-induced cell migration (Fig. 4A). The
expression and activity of MMP9 were monitored by RT-PCR and
zymography, respectively. p43 enhanced both of the expression and
activity of MMP9, and the stimulatory effect was also blocked by
PD98059 (Fig. 4D). Thus, the p43-induced endothelial cell
migration is mediated by MMP9 that is induced and activated by ERK.
JNK Mediates the p43-induced Endothelial Cell Death--
p43
induced apoptosis of endothelial cells and activated JNK from 10 nM (Figs. 2 and 3). Here we investigated whether JNK is
responsible for the p43-induced apoptosis. To address this question, we
used SB202190 that inhibits p38 MAPK at 10 µM and blocks
both p38 MAPK and JNK at 40 µM (29, 30). BAECs were pretreated with each concentration (10 or 40 µM) of
SB202190, PD98059, and the caspase-3 inhibitor, z-DEVD-fmk, and
subsequently with 20 nM p43. The induction of
apoptosis was determined by cell morphology and the activation of
caspase-3. Although the p43-induced apoptosis was not affected by
the treatment of SB202190 (10 µM) or PD98059, it was
inhibited by the pre-treatment of SB202190 (40 µM) or
z-DEVD-fmk (Fig. 5A). The
activity of JNK was determined by the phosphorylation of GST-Jun as the
reaction substrate. The phosphorylation of c-Jun was completely
inhibited only with SB202190 (40 µM) among different
inhibitors (Fig. 5B). These results suggest that JNK, but
not p38 MAPK and ERK, should be involved in the p43-induced
apoptosis.
To confirm the involvement of JNK in the p43-induced apoptosis more
specifically, we used JNK-binding domain (JBD) of JNK-interacting protein 1 or JNK dominant negative form of JNK (JNK-DN), which can
block the activity of JNK (31, 32). JNK-DN and JBD were expressed in
BAECs by adenoviral transfection as determined by immunoblotting
(data not shown). Whereas about 45% of BAECs were turned to apoptotic
cells by p43, the effect of p43 was blocked by the expression of JBD or
JNK-DN (Fig. 5C). These results clearly indicate that JNK
mediates the p43-induced apoptosis of the endothelial cells.
Deletion Mapping of p43 for Endothelial Cell Migration and
Apoptosis--
We have previously shown that the various truncated p43
fragments retained the activity inducing tumor necrosis factor and interleukin-8 (14). To determine whether the biphasic activity of p43
on endothelial cells can be separated, depending on the peptide region,
we have prepared the 146-aa N-terminal and 166-aa C-terminal domains of
p43 and compared them with the full-length p43 in the induction of
endothelial cell migration and death. In the endothelial cell
migration, all of the three polypeptides showed a
dose-dependent curve (Fig.
6A). However, the maximum effect on the cell migration was shown at 10 nM of the
C-terminal domain of p43 but at 1 nM of the full-length p43
and its N-terminal domain. All of the three polypeptides showed the
activity inducing endothelial cell death in dose-dependent
manner (Fig. 6B). In both cases, the full-length p43 showed
the highest activity, although all of the three polypeptides showed the
similar pattern of the activity. These results suggest that the
activities for the endothelial cell migration and apoptosis are not
separable by the different domains of p43, but its whole structure is
involved for the full activity.
p43 is cleaved upon apoptosis to generate its C-terminal domain,
which was previously called endothelial monocyte activating polypeptide
II (EMAP II) (13, 33). For this reason, p43 has been considered as the
precursor for the cytokine, EMAP II. However, we have recently shown
that p43, and not EMAP II, is secreted to work as a pro-inflammatory
cytokine (14). Nonetheless, EMAP II itself showed a potent
anti-angiogenic activity inducing apoptosis of endothelial cells (34,
35). In this work, we found that p43 can induce the migration as well
as death of the endothelial cells in a dose-dependent
manner (Figs. 1 and 2). Interestingly, both of the N- and the
C-terminal EMAP II domains also showed dose-dependent
bell-shaped activity in the induction of endothelial cell migration
as the full-length p43, although their activities were lower than the
full-length p43 (Fig. 6A). Thus, the two distinct activities
on endothelial cells do not seem to be determined by different
structural units but rather dispersed throughout the polypeptide of
p43. The p43-dependent signal pathway leads to the
activation ERK and MMP9 that is responsible for the endothelial cell
migration (Figs. 2 and 4). This result is consistent with the previous
reports that the ERK activation is required to induce MMP9 in vascular
smooth muscle cells and endothelial cells (36, 37). However, p43 showed
little, or very weak if any, effect on the endothelial cell
proliferation at concentrations lower than 10 nM (data not
shown). Instead, the proliferation of the endothelial cells is
inhibited by p43 at higher concentrations (Ref.
16).2 Thus, the
pro-angiogenic activity of p43 appears to result mainly from its
capability of inducing migration of the endothelial cells.
The MMP9 activity was significantly decreased at 100 nM p43
(Fig. 4B), whereas ERK still remained active (Fig. 3). In
addition, MMP9 was still weakly induced and activated when the ERK
activity was completely inhibited by the treatment of 20 µM PD98059 (Fig. 4D). Likewise, the
endothelial cell migration was not completely blocked when the ERK
activity was blocked with 20 µM PD98059 or with anti-MMP9
antibody (Fig. 4, A and C). All of these results implicate that the other signal pathways independent of ERK should be
also involved in the endothelial cell migration induced by p43.
p43 also caused apoptosis of the endothelial cells (Fig. 2) via JNK
(Fig. 5). It is known that JNK is involved in apoptosis induced by
various stimuli such as tumor necrosis factor, ceramide, irradiation,
or heat shock (31, 38, 39). The involvement of JNK in apoptosis of the
endothelial cells has been also reported previously (40). Although the
treatment of SB202190 (40 µM) completely blocked the JNK
activity (Fig. 5B), apoptosis of the endothelial cells
still occurred at a little higher rate than the p43-untreated cells
(Fig. 5A). Thus, JNK does not appear to be the only mediator
for the JNK-induced apoptosis of the endothelial cells.
Angiogenesis is a complex biological process that is determined by the
combined effect of multiple factors with different activities. For this
reason, the effect of a specific protein factor on angiogenesis may be
determined by the balance with other factors near the responding
endothelial cells. The biphasic mode of activity in a single protein
appears to give an additional complexity in the regulation of
angiogenic process. The biphasic activity has been also reported in
other signaling molecules such as transforming growth factor- Although we have previously shown that the N-terminal domain of p43 is
responsible for its secretion (14), it does not have any clear sequence
motif for secretion. Interestingly, the same domain in p43 is also
involved in its association with the multi-ARS complex (12). Also,
p43, if not associated with the complex, appears to be unstable in the
cell (8). Thus, the activity and cellular turnover of p43 appears to be
under complex control. It would be interesting to see whether p43 is
secreted independently of the multi-ARS complex or is first held
within the multi-ARS complex and then secreted upon appropriate
condition or signal.
*
This work was supported by a grant from the National
Creative Research Initiatives from the Ministry of Science and
Technology, Korea.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed: San 56-1, Shillim-dong, Kwanak-gu, Center for ARS Network, College of
Pharmacy, Seoul National University, Seoul 151-746, Korea. Tel.:
82-2-880-8180; Fax: 82-2-875-2621; E-mail: sungkim@snu.ac.kr.
Published, JBC Papers in Press, September 16, 2002, DOI 10.1074/jbc.M207934200
2
S. G. Park, Y.-S. Kang, Y. H. Ahn,
S. H. Lee, K.-R. Kim, K.-W. Kim, G. Y. Koh, Y.-G. Ko, and S. Kim, unpublished data.
The abbreviations used are:
ARS, aminoacyl-tRNA
synthetase;
RT, reverse transcription;
BAEC, bovine aorta endothelial
cells;
ERK, extracellular signal-regulated kinase;
MAPK, mitogen-activated protein kinase;
JNK, c-Jun N-terminal kinase;
DN, dominant negative;
JBD, Jun-binding domain;
VEGF, vascular epidermal
growth factor;
aa, amino acid(s);
LPS, lipopolysaccharide;
CAM, chorioallantoic membrane;
DMEM, Dulbecco's modified Eagle's
medium;
pNA, p-nitroanilide;
MMP, matrix
metalloproteinase;
GST, glutathione S-transferase;
EMAP II, endothelial monocyte activating polypeptide II.
Dose-dependent Biphasic Activity of tRNA
Synthetase-associating Factor, p43, in Angiogenesis*
,
,
,
,
, and
**
National Creative Research Initiatives
Center for ARS Network, the § Angiogenesis Research
Laboratory, College of Pharmacy, Seoul National University, Seoul
151-742 and the ¶ National Creative Research
Initiatives Center for Cardiac Regeneration, Postech, Pohang
790-784, Korea
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunit of ATP synthase (16), which
was previously shown to mediate anti-angiogenic activity of
angiostatin (17, 18). p43 is also proteolytically cleaved under
apoptotic conditions (14, 19). In addition, the C-terminal
domain shares homology with the equivalent part of mammalian
tyrosyl-tRNA synthetase that is processed to function as two distinct
cytokines (20). Another class I tRNA synthetase, tryptophanyl-tRNA
synthetase, also showed potent angiostatic activity (21). All of these
previous reports led us to expect that the secreted p43 may play an
important role in angiogenesis as well as in the inflammation process.
Here we investigated the activity of p43 in angiogenesis using various in vitro and in vivo models and found that p43
shows dose-dependent biphasic activity in angiogenesis.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-glycerophosphate, 1 mM dithiothreitol, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, and 0.1 mM phenylmethylsulfonyl
fluoride) containing protease inhibitor mixture (Roche Molecular
Biochemicals). The proteins in the lysates were resolved by 10%
SDS-PAGE and transferred onto a polyvinylidene difluoride membrane
(Millipore). Antigens were visualized by sequential treatment with
specific antibodies, horseradish peroxidase-conjugated secondary
antibodies, and an enhanced chemiluminescence substrate kit. JNK
immunocomplex in vitro kinase assay was performed as
described previously (23).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (51K):
[in a new window]
Fig. 1.
p43 induces the endothelial cell migration at
low dose. A, the coverslips containing 0, 0.1 (low), and 1 µg (high) of p43 were loaded on the chorioallantoic
membrane (circles) of the fertilized eggs, and the
p43-induced remodeling of vascularization was monitored. B,
the tube formation of BAECs was observed by phase-contrast microscopy
on the Matrigels containing 0, 1 (low), and 100 nM (high)
p43. C, the BAECs on the culture dishes were scraped with a
razor blade and allowed to migrate in the media containing 0, 1 (low),
and 100 nM (high) p43. The lines stand for the
boundary of the wounds introduced by the razor blade. D, the
effect of p43 on the endothelial cell migration was assayed as
described under "Experimental Procedures" using a Transwell chamber
with gelatin-coated polycarbonate membrane. BAECs were suspended in the
upper chamber, and the indicated concentrations of p43 were filled in
the lower chamber. VEGF (0.7 nM) was used as a positive
control. The cells migrating to the lower chambers were stained with
hematoxylin and counted in high power fields. The data are the averages
of the three independent experiments.

View larger version (39K):
[in a new window]
Fig. 2.
p43 induces apoptosis of the endothelial
cells at high dose. A, BAECs were treated with the
indicated concentrations of p43 for 24 h, and the apoptotic cells
were counted by morphological characteristics. B, BAECs were
treated with 0 (
) and 100 nM (+) p43 and followed by the
in situ apoptosis staining (green). The nuclei
were stained with propidium iodide (red). C, DNA
laddering of BAECs treated with 0 (
) and 100 nM (+) p43.
After the p43 treatment for 24 h, the nucleosomal fragmentation of
the cellular DNA was analyzed by 1.8% agarose gel electrophoresis.
D, the activities of caspase-1 and -3 were measured from
BAECs treated with 0 or 100 nM p43 for 16 h as
described under "Experimental Procedures."

View larger version (15K):
[in a new window]
Fig. 3.
Three MAPKs are differentially activated by
p43. The effect of p43 on the activities of three MAPKs (ERK1/2,
JNK, and p38 MAPK) was investigated in BAECs. BAECs were treated with
the indicated amounts of p43 for 1 h, and the activity of each
MAPK was determined as described in previously (14).
"p-" stands for the phosphorylated form of each
protein.

View larger version (48K):
[in a new window]
Fig. 4.
ERK is responsible for the p43-induced
endothelial cell migration. A, BAECs were suspended
with 20 µM PD98059 (PD) or 10 µM
of SB203580 (SB) in the upper chamber, and 1 nM
p43 was added to the lower chamber. The cell migration was monitored as
described under "Experimental Procedures." VEGF (0.7 nM) was used as positive control. B, BAECs were
treated with the indicated concentrations of p43, and the activities of
MMP2 and -9 were determined by zymographic assay as described under
"Experimental Procedures." C, the indicated amounts of
anti-MMP9 antibody were mixed with BAECS in the upper chamber in
Transwell, whereas 1 nM p43 was added to the lower chamber.
Mock IgG was added to the concentration of 5 µg/ml. The values are
the averages of the two independent experiments. D, BAECs
were pretreated with 20 µM PD98059 or 10 µM
SB203580 for 1 h and treated with 1 nM p43. For the
assays of the ERK1/2 phosphorylation, the level of the MMP9 transcript
and the activity of MMP9, BAECs were cultured for 1, 12, and 24 h,
respectively. RT-PCR and zymography were used to determine the
expression and activation of MMP9, respectively. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) shows that the equal amounts
of total RNA were used for RT-PCR.

View larger version (24K):
[in a new window]
Fig. 5.
JNK mediates for the p43-induced
apoptosis. A, BAECs were pretreated with 10 and 40 µM SB202190, 20 µM PD98059, and z-DEVD-fmk
for 1 h to inhibit p38 MAPK, JNK, ERK1/2, and caspase-3,
respectively, and then treated with 20 nM p43. The number
of the apoptotic cells and caspase-3 activity was measured 16 h
after the p43 treatment as described under "Experimental
Procedures." B, BAECs were pretreated with different
inhibitors and treated with 20 nM p43. 1 h after the
p43 treatment, the JNK activity was measured as described under
"Experimental Procedures." C, JBD (Jun-binding
domain) of Jun-interacting protein and JNK-DN were expressed in
BAECs to specifically block the activation of JNK, and the effect of
p43 (20 nM) on the cell death was compared. The values for
the apoptosis are the averages of the three independent
experiments.

View larger version (14K):
[in a new window]
Fig. 6.
Comparison of the full-length p43 and its N-
and C-terminal domains for endothelial cell migration and
death. The three different polypeptides of p43 were compared for
their activities for inducing endothelial cell migration using a
Transwell chamber (A) and cell death (B) as
described under "Experimental Procedures." p43-F,
-N, and -C stand for 1-312, 1-146, and 147-312
polypeptides of human p43.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1 (41),
thrombospondin-1 (42), and estrogen (43). Although the detailed
mechanism to control their activities may vary, the dual mode of the
activity appears to be required for the fine control of angiogenesis.
![]()
FOOTNOTES
Current address: Graduate School of Biotechnology, Korea
University, Seoul 131-701, Korea.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kisselev, L. L.,
and Wolfson, A. D.
(1994)
Prog. Nucleic Acids Res. Mol. Biol.
48,
83-142[Medline]
[Order article via Infotrieve]
2.
Mirande, M.
(1991)
Prog. Nucleic Acids Res. Mol. Biol.
40,
95-142[Medline]
[Order article via Infotrieve]
3.
Yang, D. C. H.
(1996)
Curr. Top. Cell Regul.
34,
101-136[Medline]
[Order article via Infotrieve]
4.
Rho, S. B.,
Lee, K. H.,
Kim, J. W.,
Shiba, K., Jo, Y. J.,
and Kim, S.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
10128-10133 5.
Rho, S. B.,
Lee, J. S.,
Jeong, E. J.,
Kim, K. S.,
Kim, Y. G.,
and Kim, S.
(1998)
J. Biol. Chem.
273,
11267-11273 6.
Rho, S. B.,
Kim, M. J.,
Lee, J. S.,
Seol, W.,
Motegi, H.,
Kim, S.,
and Shiba, K.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
4488-4493 7.
Kim, T.,
Park, S. G.,
Kim, J. E.,
Seol, W., Ko, Y. G.,
and Kim, S.
(2000)
J. Biol. Chem.
275,
21768-21772 8.
Kim, J. Y.,
Kang, Y. S.,
Lee, J. W.,
Kim, H. J.,
Ahn, Y. H.,
Park, H., Ko, Y. G.,
and Kim, S.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
7912-7916 9.
Quevillon, S.,
Robinson, J.-C.,
Berthonneau, E.,
Siatecka, M.,
and Mirande, M.
(1999)
J. Mol. Biol.
285,
183-195[CrossRef][Medline]
[Order article via Infotrieve]
10.
Robinson, J. C.,
Kerjan, P.,
and Mirande, M.
(2000)
J. Mol. Biol.
304,
989-994
11.
Norcum, M. T.,
and Warrington, J. A.
(2000)
J. Biol. Chem.
275,
17921-17924 12.
Park, S. G.,
Jung, K. H.,
Lee, J. S., Jo, Y. J.,
Motegi, H.,
Kim, S.,
and Shiba, K.
(1999)
J. Biol. Chem.
274,
16673-16676 13.
Shalak, V.,
Kaminska, M.,
Mitnacht-Kraus, R.,
Vandenabeele, P.,
Clauss, M.,
and Mirande, M.
(2001)
J. Biol. Chem.
276,
23769-23776 14.
Ko, Y.-G.,
Park, H.,
Kim, T.,
Lee, J.-W.,
Park, S. G.,
Seol, W.,
Kim, J. E.,
Lee, W.-H.,
Kim, S.-H.,
Park, J. E.,
and Kim, S.
(2001)
J. Biol. Chem.
276,
23028-23033 15.
Park, H.,
Park, S. G.,
Lee, J.-W.,
Kim, T.,
Kim, G., Ko, Y.-G.,
and Kim, S.
(2002)
J. Leukoc. Biol.
71,
223-230 16.
Chang, S. Y.,
Park, S. G.,
Kim, S.,
and Kang, C. Y.
(2002)
J. Biol. Chem.
277,
8388-8394 17.
Moser, T. L.,
Stack, M. S.,
Asplin, I.,
Enghild, J. J.,
Hojrup, P.,
Everitt, L.,
Hubchak, S.,
Schnaper, H. W.,
and Pizzo, S. V.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2811-2816 18.
Moser, T. L.,
Kenan, D. J.,
Ashley, T. A.,
Roy, J. A.,
Goodman, M. D.,
Misra, U. K.,
Cheek, D. J.,
and Pizzo, S. V.
(2001)
Proc. Natl. Acad. Sci. U. S. A.
98,
6656-6661 19.
Knies, U. E.,
Behrensdorf, H. A.,
Mitchell, C. A.,
Deutsch, U.,
Risau, W.,
Drexler, H. C. A.,
and Cluass, M.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12322-12327 20.
Wakasugi, K.,
and Schimmel, P.
(1999)
Science
284,
147-151 21.
Wakasugi, K.,
Slike, B. M.,
Hood, J.,
Otani, A.,
Ewalt, K. L.,
Friedlander, M.,
Cheresh, D. A.,
and Schimmel, P.
(2002)
Proc. Natl. Acad. Sci. U. S. A.
99,
173-177 22.
Wakasugi, K.,
and Schimmel, P.
(1999)
J. Biol. Chem.
274,
23155-23159 23.
Ko, Y. G.,
Kang, Y. S.,
Park, H.,
Seol, W.,
Kim, J.,
Kim, T.,
Park, H. S.,
Choi, E. J.,
and Kim, S.
(2001)
J. Biol. Chem.
276,
39103-39106 24.
Jo, H.,
Sipos, K., Go, Y. M.,
Law, R.,
Rong, J.,
and McDonald, J. M.
(1997)
J. Biol. Chem.
272,
1395-1401 25.
Fisher, C.,
Gilbertson-Beadling, S.,
Powers, E. A.,
Petzold, G.,
Poorman, R.,
and Mitchell, M. A.
(1994)
Dev. Biol.
162,
499-510[CrossRef][Medline]
[Order article via Infotrieve]
26.
Schnaper, H. W.,
Grant, D. S.,
Stetler-Stevenson, W. G.,
Fridman, R.,
D'Orazi, G.,
Murphy, A. N.,
Bird, R. E.,
Hoythya, M.,
Fuerst, T. R.,
and French, D. L.
(1993)
J. Cell. Physiol.
156,
235-246[CrossRef][Medline]
[Order article via Infotrieve]
27.
Kraling, B. M.,
Wiederschain, D. G.,
Boehm, T.,
Rehn, M.,
Mulliken, J. B.,
and Moses, M. A.
(1999)
J. Cell Sci.
112,
1599-1609[Abstract]
28.
Puyraimond, A.,
Weitzman, J. B.,
Babiole, E.,
and Menashi, S.
(1999)
J. Cell Sci.
112,
1283-1290[Abstract]
29.
Jacinto, E.,
Werlen, G.,
and Karin, M.
(1998)
Immunity
8,
31-41[CrossRef][Medline]
[Order article via Infotrieve]
30.
Porter, C. M.,
Havens, M. A.,
and Clipstone, N. A.
(2000)
J. Biol. Chem.
275,
3543-3551 31.
Verheij, M.,
Bose, R.,
Lin, X. H.,
Yao, B.,
Jarvis, W. D.,
Grant, S.,
Birrer, M. J.,
Szabo, E.,
Zon, L. I.,
Kyriakis, J. M.,
Haimovitz-Friedman, A.,
Fuks, Z.,
and Kolesnick, R. N.
(1996)
Nature
380,
75-79[CrossRef][Medline]
[Order article via Infotrieve]
32.
Harding, T. C.,
Xue, L.,
Bienemann, A.,
Haywood, D.,
Dickens, M.,
Tolkovsky, A. M.,
and Uney, J. B.
(2001)
J. Biol. Chem.
276,
4531-4534 33.
Quevillon, S.,
Agou, F.,
Robinson, J.-C.,
and Mirande, M.
(1997)
J. Biol. Chem.
272,
32573-32579 34.
Berger, A. C.,
Alexander, H. R.,
Tang, G., Wu, P. S.,
Hewitt, S. M.,
Turner, E.,
Kruger, E.,
Figg, W. D.,
Grove, A.,
Kohn, E.,
Stern, D.,
and Libutti, S. K.
(2000)
Microvasc. Res.
60,
70-80[CrossRef][Medline]
[Order article via Infotrieve]
35.
Schwarz, M. A.,
Kandel, J.,
Brett, J., Li, J.,
Hayward, J.,
Schwarz, R. E.,
Chappey, O.,
Wautier, J. L.,
Chabot, J., Lo,
Gerfo, P.,
and Stern, D.
(1999)
J. Exp. Med.
190,
341-354 36.
Genersch, E.,
Hayess, K.,
Neuenfeld, Y.,
and Haller, H.
(2000)
J. Cell Sci.
113,
4319-4330[Abstract]
37.
Khan, K. M.,
Falcone, D. J.,
and Kraemer, R.
(2002)
J. Biol. Chem.
277,
2353-2359 38.
Davis, R. J.
(2000)
Cell
103,
239-252[CrossRef][Medline]
[Order article via Infotrieve]
39.
Tournier, C.,
Hess, P.,
Yang, D. D., Xu, J.,
Turner, T. K.,
Nimnual, A.,
Bar-Sagi, D.,
Jones, S. N.,
Flavell, R. A.,
and Davis, R. J.
(2000)
Science
288,
870-874 40.
Ho, F. M.,
Liu, S. H.,
Liau, C. S.,
Huang, P. J.,
and Lin-Shiau, S. Y.
(2000)
Circulation
101,
2618-2624 41.
Pepper, M. S.,
Vassalli, J. D.,
Orci, L.,
and Montesano, R.
(1993)
Exp. Cell Res.
204,
356-363[CrossRef][Medline]
[Order article via Infotrieve]
42.
Pazouki, S.,
Pendleton, N.,
Heerkens, E.,
Smither, R. L.,
Moore, J. V.,
and Schor, A. M.
(1996)
Biochem. Soc. Trans.
24,
368S[Medline]
[Order article via Infotrieve]
43.
Banerjee, S. K.,
Campbell, D. R.,
Weston, A. P.,
and Banerjee, D. K.
(1997)
Mol. Cell Biochem.
177,
97-105[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
S. G. Park, P. Schimmel, and S. Kim Aminoacyl tRNA synthetases and their connections to disease PNAS, August 12, 2008; 105(32): 11043 - 11049. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Han, B.-J. Park, S. G. Park, Y. S. Oh, S. J. Choi, S. W. Lee, S.-K. Hwang, S.-H. Chang, M.-H. Cho, and S. Kim AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53 PNAS, August 12, 2008; 105(32): 11206 - 11211. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-J. Kim, M. C. Park, S. J. Choi, Y. S. Oh, E.-C. Choi, H. J. Cho, M. H. Kim, S.-H. Kim, D. W. Kim, S. Kim, et al. Determination of Three-dimensional Structure and Residues of the Novel Tumor Suppressor AIMP3/p18 Required for the Interaction with ATM J. Biol. Chem., May 16, 2008; 283(20): 14032 - 14040. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kim, S. H. Kim, S. Kim, D. Cho, and T. S. Kim AIMP1/p43 Protein Induces the Maturation of Bone Marrow-Derived Dendritic Cells with T Helper Type 1-Polarizing Ability J. Immunol., March 1, 2008; 180(5): 2894 - 2902. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Han, S. G. Park, B. Liu, B.-J. Park, J. Y. Kim, C. H. Jin, Y. W. Song, Z. Li, and S. Kim Aminoacyl-tRNA Synthetase-Interacting Multifunctional Protein 1/p43 Controls Endoplasmic Reticulum Retention of Heat Shock Protein gp96: Its Pathological Implications in Lupus-Like Autoimmune Diseases Am. J. Pathol., June 1, 2007; 170(6): 2042 - 2054. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Shalak, L. Guigou, M. Kaminska, M.-P. Wautier, J.-L. Wautier, and M. Mirande Characterization of p43(ARF), a Derivative of the p43 Component of Multiaminoacyl-tRNA Synthetase Complex Released during Apoptosis J. Biol. Chem., April 13, 2007; 282(15): 10935 - 10943. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Han, M. J. Lee, S. G. Park, S. H. Lee, E. Razin, E.-C. Choi, and S. Kim Hierarchical Network between the Components of the Multi-tRNA Synthetase Complex: IMPLICATIONS FOR COMPLEX FORMATION J. Biol. Chem., December 15, 2006; 281(50): 38663 - 38667. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Park, Y. S. Kang, J. Y. Kim, C. S. Lee, Y. G. Ko, W. J. Lee, K.-U. Lee, Y. I. Yeom, and S. Kim Hormonal activity of AIMP1/p43 for glucose homeostasis PNAS, October 3, 2006; 103(40): 14913 - 14918. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kim, S. H. Kim, S. Kim, and T. S. Kim The Novel Cytokine p43 Induces IL-12 Production in Macrophages via NF-{kappa}B Activation, Leading to Enhanced IFN-{gamma} Production in CD4+ T Cells J. Immunol., January 1, 2006; 176(1): 256 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Park, H. J. Kim, Y. H. Min, E.-C. Choi, Y. K. Shin, B.-J. Park, S. W. Lee, and S. Kim From The Cover: Human lysyl-tRNA synthetase is secreted to trigger proinflammatory response PNAS, May 3, 2005; 102(18): 6356 - 6361. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. G. Park, H. Shin, Y. K. Shin, Y. Lee, E.-C. Choi, B.-J. Park, and S. Kim The Novel Cytokine p43 Stimulates Dermal Fibroblast Proliferation and Wound Repair Am. J. Pathol., February 1, 2005; 166(2): 387 - 398. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Lee, B. H. Cho, S. G. Park, and S. Kim Aminoacyl-tRNA synthetase complexes: beyond translation J. Cell Sci., September 1, 2004; 117(17): 3725 - 3734. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||